BCL2L11 and acute myeloid leukemia: These include combinations with standard anti-AML agents, e.g., azacytidine32, cytarbine and idarubicin30, which induce mitochondrial priming by inducing the expressions of the BH3 domain-only proapoptosis proteins such as BIM, NOXA, and PUMA in a p53-dependent or independent manner41,55,56.